Immune System News and Research

RSS

Therapeutic equivalent to replace penicillin

Antibiotics are among the greatest achievements of medical science. But lately the former multi-purpose weapon fails in the battle against infectious diseases. Bacteria are increasingly developing resistance to antibiotics. Researchers have now found a therapeutic equivalent which could replace penicillin and related phamaceuticals.

8 Jun 2011

Single molecule telomerase activator could extend human cell life indefinitely

When expressed (turned on), the gene (hTERT) located on Chromosome number 5p15.33 activates the enzyme telomerase. Human cells can keep living and dividing indefinitely when telomerase is continually present; i.e. the cells become immortal. Telomerase Activation Sciences, Inc. (T.A. Sciences®) announces TA-65® can extend human cell life indefinitely. TA-65® is a single molecule telomerase activator that turns on the Immortality Gene under controlled laboratory conditions.

8 Jun 2011

Grifols officially merges with Talecris Biotherapeutics

Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain, today announced that it has officially begun to merge its operations with Talecris Biotherapeutics in order to function as one company, following its acquisition of Talecris on June 1.

8 Jun 2011

IAS calls on leaders to ensure inclusion of HIV cure research into international AIDS agenda

As world leaders meet this week to review progress and chart the future course of the global AIDS response at the 2011 UN General Assembly High-Level Meeting on AIDS in New York, the International AIDS Society (IAS) calls on leaders to ensure the inclusion of HIV cure research and its global strategy into the international HIV agenda and in all discussions, political decisions and funding strategies.

8 Jun 2011

GSK, Crucell to test second-generation malaria vaccine

GlaxoSmithKline and drug company Crucell, a division of Johnson & Johnson, will collaborate with the PATH Malaria Vaccine Initiative to test a second-generation malaria vaccine "within the next couple of months," Reuters reports.

8 Jun 2011

Quest conducts first clinical Investigators Meeting for Oregovomab in Rome, provides corporate updates

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announced today that it conducted its first clinical Investigators Meeting for Oregovomab in Rome, Italy.

8 Jun 2011

Lethal malaria parasite has biochemical weakness

Every year, 10,000 pregnant women and up to 200,000 newborn babies are killed by the malaria parasite. Doctors all around the globe have for years been looking in vain for a medical protection, and now researchers from the University of Copenhagen have found the biochemically weakness of the lethal malaria parasite, and will now start developing a vaccine to combat pregnancy related malaria.

8 Jun 2011

Vaccine candidate produces immune response to antigen in all strains of influenza A

A universal influenza vaccine targeting a protein common to all strains of influenza A has safely produced an immune response in humans. If proven effective, the vaccine could eliminate the practice of creating a new flu vaccine annually to match predicted strains, with major implications for global health.

8 Jun 2011

Avoiding repetitive activities that increase stress on the joints may prevent bursitis

As warm weather arrives and the great outdoors beckons, more and more men and women will be taking to the trails, the beaches, or their yards and gardens, embarking on physical activities that may result in sore, aching, swollen joints.

8 Jun 2011

Eating at wrong time of the day reduces fertility in fruit flies

Dieticians will tell you it isn't healthy to eat late at night: it's a recipe for weight gain. In fruit flies, at least, there's another consequence: reduced fertility.

8 Jun 2011

OncoSec announces additional evaluation of ElectroImmunotherapy Phase I trial on melanoma

OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that additional evaluation of a previous Phase I trial provided further evidence that a DNA plasmid encoded to produce IL-12 delivered by electroporation into melanoma lesions induces responses to known and novel antigens, resulting in regression of local treated lesions as well as distant untreated lesions.

7 Jun 2011

Unique clinical trial addresses important questions about treating AIDS-related cancers

As the world marks the 30-year anniversary of the first reporting of HIV/AIDS, now comes the realization of a new challenge for people with the incurable disease. For reasons not yet clear, people with HIV face a higher rate of cancers not usually associated with HIV. This increasing rate of "non-AIDS defining cancers" includes lung, head and neck, liver, kidney, and anal cancers, among others.

7 Jun 2011

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

BioSante Pharmaceuticals, Inc. today announced that the FDA's clinical hold on the GVAX Prostate Cancer Vaccine for the treatment of prostate cancer has been lifted by FDA.

7 Jun 2011

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

ZIOPHARM Oncology, Inc. announced today that Douglas J. Schwartzentruber, MD, FACS, of the Indiana University Health Goshen Center for Cancer Care, presented initial positive clinical results from the first-ever treatment demonstrating control over transgene encoding of a therapeutic anticancer protein in humans using a small molecule activator ligand.

7 Jun 2011

Pennsylvania reports first detection of West Nile encephalitis in Greene County

Pennsylvania has reported its earliest detection of a West Nile virus-carrying mosquito since testing began in 2000, the Department of Environmental Protection said today. The first detection of 2011 was a mosquito collection in Morgan Township, Greene County, on May 17.

7 Jun 2011

Specific forms of lymphoma create their own survival niche

Cancer cells do not grow equally well everywhere in the body. Often, they first create the conditions in which they can grow. Many years ago researchers discovered that solid tumors attract blood vessels to ensure their supply of nutrients by secreting specific factors.

7 Jun 2011

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists for the treatment of cancer, respiratory and autoimmune diseases, today announced the presentation of results from a Phase 1 clinical trial of VTX-2337, a selective TLR8 agonist in patients with advanced solid tumors. Data were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline.

7 Jun 2011

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Symphogen announced today preliminary primary endpoint data on 12 of 20 patients enrolled in the first Phase 1 clinical trial with their lead cancer compound, Sym004.

7 Jun 2011

PATH malaria vaccine initiative to collaborate with GSK and Crucell in development of 2nd-generation malaria vaccine

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline (GSK). This collaboration is aimed at developing a second-generation vaccine against malaria—a deadly disease that kills close to 800,000 people annually, most of them young children under age five in Africa. MVI drives the development of malaria vaccines by joining its scientific, managerial, and field expertise with companies, universities, and governments to test potential malaria vaccines and invest in those with the most promise.

6 Jun 2011

Immune System News and Research

Therapeutic equivalent to replace penicillin

Single molecule telomerase activator could extend human cell life indefinitely

Grifols officially merges with Talecris Biotherapeutics

IAS calls on leaders to ensure inclusion of HIV cure research into international AIDS agenda

GSK, Crucell to test second-generation malaria vaccine

Quest conducts first clinical Investigators Meeting for Oregovomab in Rome, provides corporate updates

Lethal malaria parasite has biochemical weakness

Vaccine candidate produces immune response to antigen in all strains of influenza A

Avoiding repetitive activities that increase stress on the joints may prevent bursitis

Eating at wrong time of the day reduces fertility in fruit flies

OncoSec announces additional evaluation of ElectroImmunotherapy Phase I trial on melanoma

Unique clinical trial addresses important questions about treating AIDS-related cancers

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Pennsylvania reports first detection of West Nile encephalitis in Greene County

Specific forms of lymphoma create their own survival niche

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

PATH malaria vaccine initiative to collaborate with GSK and Crucell in development of 2nd-generation malaria vaccine

Understanding the DNA Damage Response in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News